rs114431066 - DLG1-AS1 - LINC02012
Magnitude 4.5 · 1 study on file
Reported associations
-
Sulfasalazine‐Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus - Unknown journal (n.d.) · Unknown authors · PubMed 28762467
ABSTRACT: Agranulocytosis is a serious, although rare, adverse reaction to sulfasalazine, which is used to treat inflammatory joint and bowel disease. We performed a genome‐wide association study comprising 9,380,034 polymorphisms and 180 HLA alleles in 36 cases of sulfasalazine‐induced agranulocytosis and 5,170 population controls. Sulfasalazine‐induced agranulocytosis was significantly associated with the HLA region on chromosome 6. The top hit (rs9266634) was located close to HLA‐B, odds ratio (OR) 5.36 (95% confidence interval (CI) (2.97, 9.69) P = 2.55 × 10−8). We HLA‐sequenced a second cohort consisting of 40 cases and 142 treated controls, and confirmed significant associations with HLA‐B*08:01, OR = 2.25 (95% CI (1.02, 4.97) P = 0.0439), in particular the
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Bloodwork
-
Complete blood count if taking sulfasalazine Moderate
Monitor for agranulocytosis development, which can be detected early by white blood cell count reduction
Baseline CBC before starting sulfasalazine, then every 1-4 weeks during initial therapy
Discuss with your doctor
-
Sulfasalazine safety and monitoring before use Moderate
Early detection of agranulocytosis via CBC monitoring can mitigate risk if sulfasalazine is medically necessary
If needed, baseline CBC before starting and frequent monitoring during treatment
Drug interactions
-
sulfasalazine Moderate
Genetic variant associated with 8.6-fold increased risk of agranulocytosis when exposed to sulfasalazine
Discuss alternative medications with your doctor